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Summary
 
Activation, anergy, and apoptosis are all possible outcomes of T cell receptor (TCR) engage-
ment. The first leads to proliferation and effector function, whereas the others can lead to par-
tial or complete immunological tolerance. Structural variants of immunizing peptide–major
histocompatibility complex molecule ligands that induce selective lymphokine secretion or an-
ergy in mature T cells in association with altered intracellular signaling events have been de-
scribed. Here we describe altered ligands for mature mouse CD4
 
1
 
 T helper 1 cells that lead to
T cell apoptosis by the selective expression of Fas ligand (FasL) and tumor necrosis factor
(TNF) without concomitant IL-2, IL-3, or interferon 
 
g
 
 production. All ligands that stimulated
cell death were found to induce FasL and TNF mRNA expression and TCR aggregation
(“capping”) at the cell surface, but did not elicit a common pattern of tyrosine phosphorylation
of the TCR-associated signal transduction chains. Thus, TCR ligands that uniquely trigger T
cell apoptosis without inducing cytokines that are normally associated with activation can be
identified.
 
T
 
cell receptor (TCR) engagement can lead to several
different responses in mature peripheral T lympho-
cytes, including activation and proliferation, anergy, and
programmed cell death (apoptosis). These events are con-
trolled by signals resulting from interaction of the TCR
and CD4 or CD8 coreceptors with peptide–MHC com-
plex ligands and contribute to the quality and extent of the
T cell response. Structural variants of a TCR ligand can se-
lectively affect individual effector functions and biochemi-
cal events in T cells (1–5). Introduction of amino acid sub-
stitutions in the peptide component of an agonist ligand for
a given T cell may variously result in the formation of: (
 
a
 
) a
nonagonist that elicits no T cell effector function; (
 
b
 
) a
weaker or stronger agonist that elicits all T cell effector
functions with a different dose response from the original
ligand; (
 
c
 
) a partial agonist with the capacity to induce a
subset of effector functions or anergy in T cells; or (
 
d
 
) an
antagonist that diminishes the response to agonists. The
discovery of these functional classes of variant TCR ligands
promoted the notion that T cells can sense the “quality” as
well as the “quantity” of TCR engagements (1–5). This
concept has been strengthened by recent evidence for
unique patterns of early tyrosine phosphorylation events
induced by variant TCR ligands that cannot be seen in re-
sponse to agonists (2, 3, 6).
The activation state of a T cell also dictates the outcome
of interactions between the TCR and the peptide–MHC
ligand. Agonist ligands stimulate lymphokine production
and proliferation in resting T cells, whereas in cycling cells,
they cause lymphokine production followed by death via
apoptosis (7, 8). The differential signaling capacity of the
TCR prompted us to investigate whether variant ligands
that selectively induce T cell death without effector activa-
tion might exist. Such ligands could be useful for dissecting
the signaling pathways leading to apoptosis as well as for
developing effective immunotherapeutic agents. We there-
fore screened numerous variants of the pigeon cytochrome
 
c 
 
(PCC)
 
1
 
 88–104 peptide for the ability to trigger apoptosis
in an activated murine CD4
 
1
 
 T cell clone against PCC/I-
E
 
k
 
 without inducing activation cytokines such as IL-2, IL-3,
or IFN-
 
g
 
. We have identified altered TCR ligands with
selective death-inducing activity and report the initial char-
acterization of their effects on activated T cells.
 
Materials and Methods
 
T Cell Clones and APCs.
 
CD4
 
1
 
 A.E7 Th1 cells (9) were
maintained by biweekly stimulation with PCC protein (5 
 
m
 
M)
and irradiated splenocytes from B10.A (H-2
 
a
 
) mice. A.E7 cells
 
1
 
Abbreviations used in this paper:
 
 Fas-L, Fas ligand; PCC, pigeon cyto-
chrome 
 
c
 
; WT, wild-type.
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stimulated in this manner 2 d previously were ficolled and trans-
ferred to fresh medium containing IL-2 (50–100 IU/ml recombi-
nant human IL-2 (Chiron, Emeryville, CA) or 10–15% T-Stim
 
TM
 
(Collaborative Biomedical Products, Bedford, MA) and incu-
bated for an additional 2–5 d to generate cycling A.E7 cells that
are predisposed to apoptosis after TCR engagement (8). P13.9, L
cell transfectants expressing I-E
 
k
 
, intercellular adhesion molecule
1 (ICAM-1), and B7.1 (CD80) molecules, were used as APCs (3).
 
Peptides.
 
PCC (88–104) is KAERADLIAYL
 
K
 
QATAK. Pep-
tides Y99, C99, R99, A99 are synthetic peptides in which the
primary TCR contact residue, lysine in position 99, is changed to
tyrosine, cysteine, arginine, or alanine, respectively. All peptides
were synthesized by the Peptide Synthesis Facility, NIAID, Na-
tional Institutes of Health [NIH], Bethesda, MD.
 
Cell Death Assays.
 
5 
 
3
 
 10
 
4
 
 P13.9 cells were incubated with
5 
 
3
 
 10
 
4
 
 cycling A.E7 cells in the presence of various concentra-
tions of PCC peptides in quadruplicate in 96-well round bot-
tomed plates. To block apoptosis, Fas-Fc and TNFR-Fc (10 
 
m
 
g/ml;
gift from Dr. David Lynch, Immunex, Seattle, WA) were in-
cluded in some assays. Cells were harvested after 24 h of incuba-
tion, two of each four wells were pooled, and 10 
 
m
 
g/ml of pro-
pidium iodide were added. Ungated cells were acquired for 30 s
at a constant flow rate using a FACScan
 
Ò
 
 equipped with CellQuest
software (Becton-Dickinson, Mountain View, CA) and the num-
ber of viable A.E7 cells in each sample was calculated as previ-
ously described (10, 11). In some experiments, P13.9 cells were
preloaded with 0.1 
 
m
 
M carboxyfluorescein diacetate-acetylester
(CMFDA; Molecular Probes, Inc., Eugene, OR) to allow APCs
to be excluded from the analysis by gating on fluorescein-nega-
tive cells. In other experiments, A.E7 cells were stained with flu-
oresceinated anti-CD4 before flow cytometry to differentiate
them from APCs.
 
Cytokine Measurement.
 
Supernatants from the apoptosis assays
were harvested at 24 h and assayed for cytokine production by
ELISA. IL-2 and IL-3 were detected using antibodies purchased
from PharMingen (San Diego, CA), essentially as per the manu-
facturer’s instructions. IFN-
 
g
 
 was measured by ELISA as previ-
ously described (6). Data are expressed as the mean of quadrupli-
cate wells calculated as a percentage of the response to 100 
 
m
 
M
wild-type (WT) peptide.
 
mRNA Analysis by Semiquantitative Reverse Transcriptase PCR.
 
A.E7 cells were incubated with P13.9 cells prepulsed for 2 h with
100 
 
m
 
M of the indicated peptides and total RNA was isolated us-
ing RNAzol according to the manufacturer’s instructions (Tel-
test, Inc., Friendswood, TX). The reverse transcriptase (RT) re-
action was performed using random hexamer primers and part of
each sample was subjected to PCR amplification using 
 
b
 
-actin
primers and 
 
32
 
P-labeled nucleotides (12). Serial dilutions of RT
products were used to ensure comparisons were in the linear
range. After normalizing the input cDNA to the 
 
b
 
-actin signal,
 
b
 
-actin, Fas ligand (L), TNF-
 
a
 
, IL-2, IFN-
 
g
 
 and Bcl-X primers
were then used to amplify their respective cDNA under the same
conditions. The PCR protocol was 95
 
8
 
C for 30 s, 55
 
8
 
C for 30 s,
72
 
8
 
C for 60 s, for 30 cycles. Sequences of the primers are as fol-
lows: 
 
b
 
-actin, 5
 
9
 
 primer (5
 
9
 
GAT GAC GAT ATC GCT GCG
CTG3
 
9
 
), 3
 
9
 
primer (5
 
9
 
GTA CGA CCA GAG GCA TAC
AGG3
 
9
 
); mIL-2, 5
 
9
 
 primer (5
 
9
 
ATG TAC AGC ATG CAG CTC
GCA TC3
 
9
 
), 3
 
9
 
 primer (5
 
9
 
GGC TTG TTG AGA TGA TGC
TTT GAC A3
 
9
 
); mFas-L, 5
 
9
 
 primer (5
 
9
 
CTG GTG GCT CTG
GTT GGA AT3
 
9
 
), 3
 
9
 
 primer (5
 
9
 
GTT TAG GGG CTG GTT
GTT GC3
 
9
 
); mTNF-
 
a
 
, 5
 
9
 
 primer (5
 
9
 
 ATG AGC ACA GAA
AGC ATG ATG CGC3
 
9
 
), 3
 
9
 
 primer, (5
 
9
 
CCA AAG TAG ACC
TGC CCG GAC TC3
 
9
 
); Bcl-X, 5
 
9
 
primer, (5
 
9
 
CAA TGG TGG
CTG AAG AGA3
 
9
 
), 3
 
9
 
 primer, (5
 
9
 
GGA GAG CGT TCA GTG
ATC3
 
9
 
).
 
Protein Biochemistry.
 
2–5 
 
3
 
 10
 
6
 
 P13.9 APCs were incubated
for 2–4 h in 200 
 
m
 
l complete medium alone (no Ag) or with the
indicated peptides at 100 
 
m
 
M. Pulsed APCs were then centri-
fuged together with 1–1.25 
 
3
 
 10
 
7
 
 cycling A.E7 cells in Eppen-
dorf tubes and warmed to 37
 
8
 
C, as described (6). After stimula-
tion, T cells 
 
1
 
 APCs were lysed (6) and lysates were then
subjected to immunoprecipitation with anti-CD3
 
e
 
 (500A2 mAb;
PharMingen), anti–ZAP-70 (rabbit antiserum; gift from Dr. L.
Samelson, NICHD, NIH, Bethesda, MD), or anti–TCR-
 
z
 
 (rab-
bit antiserum; gift from Dr. J. Bolen, DNAX, Palo Alto, CA; 13).
Immunoprecipitates were resolved by SDS-PAGE, transferred to
nitrocellulose, and blotted with antiphosphotyrosine antibody (6).
Blots were developed using SuperSignal
 
TM
 
 chemiluminescent
substrate (Pierce Chemical Co., Rockford, IL).
 
Fluorescence Microscopy.
 
10
 
6
 
 P13.9 APCs were incubated for
2–4 h in 200 
 
m
 
l complete medium alone (NP) or with the indi-
cated peptides at 100 
 
m
 
M. Pulsed APCs were then centrifuged
together with 10
 
6
 
 cycling A.E7 cells in Eppendorf tubes and
warmed to 37
 
8
 
C for 5 min. Cells were incubated on ice for 5 min
and an additional 15 min in presence of 10 
 
m
 
g/ml of anti-CD3
Ab (PharMingen), washed twice with cold PBS, and fixed for 30
min at room temperature in 1% PFA. For the detection of actin
polymerization, A.E7 cells were similarly stimulated with APCs
and different variant peptides. Cells were fixed for 30 min at
room temperature in 1% PFA, washed twice in PBS 1% FCS and
incubated 30 min in PBS/0.1% saponin/1% FCS/Texas red con-
jugated–X phalloidin (2 U/ml). Cells were washed twice with
PBS and were mounted on slides using Fluoromount-G
 
TM
 
 (Elec-
tron Microscopy Sciences, Fort Washington, PA). The images were
obtained on a Zeiss Axiophot (Carl Zeiss, Inc., Thornwood, NY)
with a CCD camera (Princeton Instruments, Inc., Trenton, NJ).
 
Results
 
Variant Ligands Induce Apoptosis without the Production of
Activation Lymphokines such as IL-2, IL-3, or IFN-
 
g
 
.
 
To
determine whether variant ligands can selectively elicit ap-
optosis responses, we screened many peptides with single
amino acid substitutions at the major epitopic residue
(lysine 99) of the agonist 88–104 peptide of PCC (PCC
88-104) for their effect on A.E7 cells that were actively cy-
cling under the influence of IL-2. Certain variants of PCC
88-104 with substitutions at position 99 have been previ-
ously found to induce variant signaling in unactivated, rest-
ing A.E7 cells (3). These substitutions do not affect binding
to the I-E
 
k
 
 molecule and therefore are assumed only to al-
ter TCR recognition of peptide–MHC ligand (3, 14). In
our study of cycling A.E7 cells, we observed that the WT
PCC 88–104 peptide induces both cell death and the secre-
tion of IL-2, IL-3, and IFN-
 
g
 
 (Fig. 1 
 
A
 
). In contrast, at
high concentrations, two of the variant peptides tested,
Y99 and C99, induce as much cell death as the WT pep-
tide, but fail to induce IL-2, IL-3, or IFN-
 
g
 
 production
(Fig. 1 
 
A
 
). T cell death under these circumstances has the
morphological and nuclear fragmentation characteristics of
apoptosis (8 and data not shown). Other variant peptides,
such as A99 and R99, do not stimulate either apoptosis or
lymphokine secretion (Fig. 1 
 
A
 
). To address the possibility 
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that the selective cell death induction by Y99 and C99 was
due to weak stimulation of all effector functions, we com-
pared dose-response curves for apoptosis and lymphokine
responses. The apoptosis assay is slightly more sensitive
than the cytokine ELISAs (Fig. 1 
 
B); however, 50% maxi-
mal apoptosis requires z1 nM WT ligand (Fig. 1 B) or 1
mM Y99 (Fig. 1 D). Because half-maximal cytokine pro-
duction in response to the WT peptide requires at most 10-
fold more agonist than half-maximal apoptosis, cytokine
production should be seen with 10 mM Y99 assuming the
latter simply behaves as a weak agonist. Yet 100 mM of
Y99 or C99 causes no production of IL-2, IL-3, or IFN-g
(Fig. 1 D and data not shown). We conclude that Y99 and
C99 are true partial agonists for A.E7 cells, because they in-
duce apoptosis but not other typical effector functions. By
contrast, R99 and A99 fail to induce these responses at any
dose and are therefore nonagonists with respect to the re-
sponses we have examined (Fig. 1 C and data not shown).
T Cell Death Induced by Partial Agonists Uses the Fas and
TNF Pathways. Because T cell apoptosis can result from
the action of Fas or TNF (15–18), we assessed the role of
these molecules in cell death induced by the Y99 and C99
partial agonists. Stimulation of cycling A.E7 cells for 2 h
with the apoptogenic WT, Y99, or C99 peptides induced
the mRNAs for TNF and Fas-L but not for Bcl-X, a pro-
tein that prevents apoptosis (19; Fig. 2 A). There was less
induction of these mRNAs with the variants compared to
the WT peptide, in accordance with the latter’s greater le-
thality at low concentrations (Fig. 1). Fas-L or TNF
mRNA levels were not increased using the nonagonist
peptides A99 and R99 (Fig. 2 A). Both Fas-L and TNF
were functionally important in the apoptosis caused by the
WT, C99, and Y99 peptides because death was potently
inhibited by reagents that specifically block these cytokines
(Fig. 2 B). In contrast to the WT peptide, none of the vari-
ants elicited IL-2 (Fig. 2 A) or IFN-g mRNA (data not
shown), confirming the results obtained by ELISA (Fig. 1).
Tyrosine Phosphorylation Patterns Induced by Variant Ligands.
In resting T cells, partial agonist or antagonist ligands generate
unique patterns of protein tyrosine phosphorylation (2, 3,
6). Hence, we determined whether apoptosis-inducing variant
peptides produce characteristic TCR-associated phosphoryla-
tion patterns in cycling T cells. CD3-e, ZAP-70, or TCR-z
(Fig. 3, A, B, and C, respectively) and their associated pro-
teins were immunoprecipitated from lysates prepared from
A.E7 cells that had been briefly stimulated with WT and
variant ligands. In cycling A.E7 cells, the WT peptide in-
duced prominent tyrosine-phosphorylated species, includ-
ing the three isoforms of phospho-z (p18, p21, and p23),
phosphorylated CD3-e, and phosphorylated ZAP-70 (Fig.
3, A and B, lane 2). This is the same pattern as that ob-
tained when resting A.E7 cells were stimulated with the
Figure 1.( A ) Variant ligands in-
duce apoptosis of CD41 Th1 cells
without the accompanying produc-
tion of IL-2, IL-3, or IFN-g. (B–D)
Dose-response analyses of cycling
A.E7 cells stimulated by P13.9 APCs
incubated with PCC (88–104) WT
peptide (B), variant peptide R99
(C), or variant peptide Y99 (D). T
cell apoptosis (solid square), IL-2 (dia-
mond), IL-3 (circle), and IFN-g (trian-
gle) production in cycling A.E7 cells
was measured after stimulation for
24 h with P13.9 APCs in the pres-
ence of the indicated concentrations
of WT peptide or variant analogues.
All values are expressed as a percent-
age of the response obtained with
100  mM of the WT peptide. The ac-
tual 100% maximal values were as
follows: apoptosis, 55% dead cells at
24 h; IL-2, 1.4 ng/ml; IL-3, >250
ng/ml; IFN-g, 120 ng/ml. All error
bars are shown and represent one SD
from the mean.352 T Cell Apoptosis by Variant Peptides
WT peptide (3). However, we found no correlation be-
tween the pattern of TCR-z tyrosine phosphorylation and
programmed cell death. The apoptosis-inducing partial ag-
onist, C99, and the nonagonist ligands, A99 and R99, all
produced a modest increase in the p21 form of phospho-z
(Fig. 3, A–C, lanes 3–5). However, the partial agonist Y99
surprisingly failed to induce a detectable increase in p21
phospho-z, even upon examination by direct anti-z immu-
noprecipitation (Fig. 3, A–C, lane 6). None of the variant
ligands induced detectable levels of the other species of
phospho-z (p18 and p23), phosphorylated CD3-e, or phos-
phorylated ZAP-70 (Fig. 3, A and B, lanes 3–6).
Ligands that Deliver Death-inducing Signals Induce TCR
Capping. Successful activation of resting T cells with an
agonist peptide causes the redistribution of the TCR into
polarized focal aggregates on the membrane, known as
“capping” (20). We examined by fluorescent microscopy
the ability of the variant ligands to induce TCR aggrega-
tion and actin polymerization after stimulating A.E7 cells
for 5 min. We observed TCR polarization at points of
contact with the APCs after stimulation with the WT pep-
tide and the apoptosis-inducing Y99 and C99 peptides but
not by the A99 peptide which, by itself, does not induce
cell death. The aggregation of the TCR correlated closely
with actin polymerization detected after intracellular stain-
ing of A.E7 cells 1 APCs with Texas red–conjugated X
phalloidin (Fig. 4). However no distinct capping or TCR
polarization was seen after stimulation with the variants
R99 (data not shown) and A99 (Fig. 4), which fail to cause
apoptosis even though they induced readily detectable z-chain
phosphorylation.
Figure 2. Induction of T cell death by partial agonists is mediated by
both the Fas and TNF pathways. (Left) mRNA expression by semiquanti-
tative RT-PCR analysis of b-actin, IL-2, Fas-L, TNF-a, and Bcl-X in
cycling A.E7 cells stimulated with variant or WT ligands. Cycling A.E7
cells were stimulated for 2 h with P13.9 APCs preincubated with either
medium (no Ag) or 100 mM of the WT or variant peptides as indicated.
Dilutions of the RT product were pretested to ensure that the PCR reac-
tion was in the linear range. (Right) Fas-L and TNF blocking of variant
ligand-induced cell death of A.E7 cells. Cycling A.E7 cells were stimu-
lated with APCs prepulsed with 2.5 nM WT, 100 mM C99, or 100 mM
Y99 peptides, in medium alone or in the presence of either Fas-Fc (10
mg/ml), TNFR-Fc (10 mg/ml), or both Fas-Fc and TNFR-Fc as indi-
cated. A.E7 cell death was measured as described in Materials and Meth-
ods and data are expressed as the percentage of dead cells. In control ex-
periments, Fas-Fc and TNFR-Fc alone did not induce proliferation or
apoptosis. Error bars represent one SD of the mean.
Figure 3. Effect of variant peptide stimulation on early tyrosine phos-
phorylation in cycling A.E7 cells. Tyrosine phosphorylation of major pro-
tein species (indicated on left) coprecipitating with CD3-e (A), ZAP-70
(B), or TCR-z (C), revealed by immunoprecipitation followed by SDS-
PAGE and phosphotyrosine immunoblotting. For each lane, 107 cycling
A.E7 cells were stimulated for 10 min with 5 3 106 P13.9 APCs
prepulsed with the indicated peptides. The arrowhead in C identifies a
55–60-kD phosphorylated protein coprecipitating with z after stimulation
with C99 or Y99, the only two variants capable of inducing A.E7 cell
death. The anti-z antiserum used here preferentially precipitates the p21
form of phospho-z, resulting in underdetection of the p23 species (C).
SDS-PAGE was performed on a 12% gel under reducing conditions. The
migration of prestained molecular weight markers is indicated on the
right. B–D are from the same experiment, whereas A is from a separate
experiment.353 Combadière et al.
Discussion
A key difference between resting and cycling mature T
cells is that antigen will stimulate lymphokine production
and proliferation in resting cells, whereas it will stimulate
lymphokine production and apoptosis in cycling T cells (8).
Death of cycling T lymphocytes occurs as part of a homeo-
static feedback control mechanism and can be used to ame-
liorate the autoimmune demyelinating disease, experimen-
tal allergic encephalomyelitis, in mice (21, 22). For the first
time, we have examined the biological and signaling prop-
erties of TCR interaction with variant peptide–MHC class
II molecule ligands in cycling T cells. We used ligands that
differ in a key TCR contact residue in an attempt to influ-
ence the quality of TCR engagement by altering the
TCR–peptide–MHC conjugate. Cytochrome c peptide
variants at position 99, as we have used here (Y99, C99,
A99, and R99) have been shown to bind Ek with the same
affinity but to bind differently to the TCR through resi-
dues in the CDR3 (14). We have discovered that Y99 and
C99 represent a novel class of variant ligands that induce
autoregulatory apoptosis of A.E7 cells without secretion of
numerous cytokines (IL-2, IL-3, IFN-g) whose production
typically accompanies TCR signaling of Th1 clones such as
A.E7. This contrasts with the WT agonist, which causes
both T cell death and cytokine production. For A.E7 cells,
we have not detected any ligands that induce activation cy-
tokines without apoptosis. The discovery of TCR ligands
that induce death without other effector functions leads
one to consider whether other ligands could possibly elicit
cytokine secretion without death. Models suggesting a hi-
erarchy of T cell responses do not support this possibility.
However, if distinct signaling pathways for each effector
response exist, then novel variants that stimulate activation
cytokines without apoptosis might be found (2, 3).
We observed similarities and differences in the signalling
events triggered by the WT agonist and the selectively apop-
togenic variant peptides, C99 and Y99. Each of the pep-
tides that caused apoptosis shared the ability to induce
TCR polarization in the membrane, as well as Fas-L and
TNF gene activation. At the same time, stimulation with
these ligands did not result in a consistent pattern of TCR-
subunit phosphorylation, as the WT and C99 ligand in-
duced clear-cut z chain phosphorylation, but the Y99
ligand failed to do so. Moreover, the C99 and Y99 partial
agonists failed to induce other tyrosine phosphorylation
signals involving CD3-e and the ZAP-70 kinase, which
correlated with their failure to induce IL-2, IL-3, and IFN-g
expression. However, despite the absence of these phos-
phorylation events, the C99 and Y99 peptides induce Fas-L
and TNF at levels sufficient to cause death. Thus, the TCR
signals associated with the induction of death cytokines are
potentially different from the signals necessary for inducing
activation lymphokines.
Our observations concerning signal transduction are sur-
prising in the context of standard models of WT and vari-
ant ligand signaling. Most current hypotheses are based on
the lower affinity of altered ligands for the TCR and pro-
pose that the variation in TCR phosphorylation seen with
such rapidly dissociating ligands arises from their short time
of TCR engagement (1, 4, 5, 23, 24). In these models,
only a subset of signaling events and effector functions
would be induced by the variant ligands because there is
rapid loss of ligand–TCR contact. If cellular responses are
directly linked to the sequential set of signaling events that
occur over time, one would expect a consistent pattern of
signaling for ligands capable of inducing similar functional
responses. We do not observe a consistent pattern of phos-
phorylation associated with the ability of peptides to cause
apoptosis, despite the shared ability of the apoptosis-induc-
ing ligands to cause TCR aggregation and actin polymer-
ization. However, engagement of the TCR may elicit both
positive and negative regulatory feedback loops that com-
pete kinetically to control the extent and duration of recep-
tor phosphorylation. As such, all ligands might initiate sim-
Figure 4. Variant TCR ligands that induce programmed cell death
promote TCR aggregation. Cycling A.E7 cells were stimulated with
P13.9 APCs pulsed with medium alone (NP) or with the indicated pep-
tides at 100 mM for 5 min at 378C. Cells were stained with fluorescein-
ated anti-CD3 Ab (PharMingen) (left) and Texas red conjugated–X phal-
loidin (right). Slides were analyzed by fluorescence microscopy. Arrows
indicate TCR or actin aggregation. Small cells are A.E7 T cells (T) and
larger cells are APCs.354 T Cell Apoptosis by Variant Peptides
ilar early signaling events, including immunoreceptor tyrosine-
based activation motif (ITAM) phosphorylation (which is re-
quired for active polarization of the TCR), but may differ
in the extent to which phosphatase recruitment has oc-
curred at the time the cells are lysed for biochemical analy-
sis. Alternatively, one must consider the possibility that a
complex alteration in TCR signal generation arising from
conformational properties of the altered ligand–TCR inter-
action, rather than simple kinetics, accounts for the selec-
tive induction of apoptosis.
Because mature T cell apoptosis is a powerful mecha-
nism for establishing peripheral immune tolerance, the new
class of variant ligands described here, which selectively in-
duce apoptosis of the responding T cell, constitute a new
type of potentially valuable immunomodulatory reagent.
The availability of apoptosis-inducing peptides that do not
elicit lymphokine secretion could permit the elimination of
activated T cells without the possibility of exacerbating dis-
ease by the simultaneous release of inflammatory mediators.
Likewise, selective death-inducing responses to self-ligands
recognized by peripheral T cells as partial agonists, might
be envisioned to play a natural role in preventing destruc-
tive autoimmune disease by eliminating self-reactive T cells
without allowing them to expand or cause inflammation.
Further experimentation will be needed to address these
possibilities.
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